The GBA Multimodal Study in Parkinson's Disease
Multimodal Molecular Imaging and Biometric Analysis in GBA-PD and Asymptomatic GBA-mutation Carriers
Pacific Parkinson's Research Centre
25 participants
May 1, 2019
OBSERVATIONAL
Conditions
Summary
This study plans to analyze the molecular and clinical mechanisms of the relationship between the GBA mutations and Parkinson's disease. This will be assessed through the use of advanced neuroimaging techniques called PET (positron emission tomography) to study the accumulation of the tau protein and the dysfunction of acetylcholine and dopamine in the brain of people with a mutation in the GBA gene, with and without Parkinson's disease. The ingestigators will also use a technology-based assessment to study the typing patterns as possible biomarkers of early motor dysfunctions.
Eligibility
Inclusion Criteria2
- heterozygous for a pathogenic GBA mutation (e.g., p.L444P, p.N370S) or polymorphism;
- age 18 to 80 years.
Exclusion Criteria5
- co-occurrence of other neurological disorders;
- implants that contraindicate the MRI scanning (e.g. cardiac pacemaker, ferromagnetic implants or devices);
- severe claustrophobia;
- intolerance to antiparkinsonian drug withdrawal (for GBA-PD subjects);
- ongoing treatment with cholinergic drugs
Interventions
3 PET scans to analyze the dopamine metabolism, acetylcholine and tau protein deposition in the brain.
Analysis of free-text typing in a computer and/or a touch-screen device.
Locations(3)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04101968